Delafloxacin

BreastfeedingGeriatricPediatric
  • TRADE NAME: Baxdela (Melinta)
  • INDICATIONS: Acute bacterial skin and skin structure infections caused by designated susceptible bacteria
  • CLASS: Antibiotic, fluoroquinolone
  • HALF-LIFE: 4–9 hours

FDA APPROVAL DATE: 06/19/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
Insufficient evidence to inform drug-associated risk

Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.

Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis.

SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS, and EXACERBATION OF MYASTHENIA GRAVIS

See full prescribing information for complete boxed warning.

Our database has 55 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
HEMATOLOGIC
OTIC
OCULAR
LOCAL
OTHER


Page last updated 10/16/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric